Inexpensive drug protects against COVID-19 inflammation in pre-clinical trials
A drug called topotecan (TPT) was administered to mice up to four days after COVID-19 infection, reducing inflammation and morbidity.
List view / Grid view
A drug called topotecan (TPT) was administered to mice up to four days after COVID-19 infection, reducing inflammation and morbidity.
A novel artificial intelligence (AI) technique called ProteinGAN has shown success at studying well known proteins to develop new ones.
Researchers have shown that prime editing is able to effectively edit genes in mice but without the off-target effects of CRISPR.
Researchers have revealed that T cells in blood samples from people who recovered from COVID-19 responded to SARS-CoV-2 variants.
Researchers have created a single-celled synthetic organism able to grow and divide that could be used to produce drugs and detect disease.
A new hydrogel has been shown to convert cancer cells to cancer stem cells within 24 hours, in six different human cancer cell line types.
Researchers have used imaging mass cytometry to analyse the cellular landscape of diseased lung tissue in severe COVID-19, revealing insights into the disease.
A mAb could be used in tooth regeneration therapy, after a single administration generated new teeth in mice and ferrets.
A new delivery vector using platelets has shown success in pre-clinical trials at delivering photothermal particles and immunostimulators to tumours.
A study has revealed that blocking a molecule called IRE1α could prevent the release of neutrophil extracellular traps in lupus pathogenesis.
An aptamer that can bind a different part of SARS-CoV-2 than known inhibitors could enhance treatments against coronavirus mutations.
Researchers have revealed that the protein ALYREF promotes the effects of the neuroblastoma gene, MYCN, making it a target.
Researchers have shown that SARS-CoV-2 infects mouth cells, which could inform the development of treatments against the oral symptoms of COVID-19.
The combination of mAbs and remdesivir induced an 80 percent protection rate against Marburg virus in rhesus macaques, according to a new study.
Researchers have created an immune assay that can profile host immune responses to infection and is faster than current methods.